MRNA
Moderna, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Moderna (MRNA) Stock: Buy, Sell, or Hold?
$231.35
-17.34 (-6.97%)
âŧ
5d:
-4.19%
30d:
+2.23%
90d:
+265.37%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 06, 2026
0d
Protect MRNA Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (34%)
Quality Score
39/100
Position
FAIR
30-Day Fair Range
$203.77 â $244.93
Position: FAIR
Forward P/E & Valuation
-53.3x
Next 12M consensus est.
Wall Street Target
$158.47
-31.5% vs target
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$217.22 / $280.80
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: MRNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 12, 2026 at $241.78 · last confirmed Nov 12, 2026
Strength: 6.6/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $231.35, which is considered fair relative to its 30-day fair value range of $203.77 to $244.93.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $217.22, while resistance sits at $280.80. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: MRNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $158.47. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $217.22, while resistance sits at $280.80. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: MRNA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $158.47. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$203.77 -
$244.93
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
34.2%
Trading Range & Key Levels
30-Day Trading Range
$203.77 -
$244.93
Current vs Trading Range
FAIR
Support Level
$217.22
Resistance Level
$280.80
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding MRNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BEARISH: Trading 31.5% above Wall St target ($158.47)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-53.33
Wall Street Target
$158.47
(-31.5%)
Revenue Growth (YoY)
29.2%
Earnings Growth (YoY)
-85.1%
Profit Margin
-110.5%
Share MRNA Analysis
Share this live MRNA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (MRNA)
Bullish
7 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
6 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Moderna aims to launch individualized cancer treatment intismeran in collaboration with Merck by 2027, following positive phase III melanoma trial results.
Key Retail Themes:
Cancer therapy development
Regulatory approvals
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 8:48 PM ET
Data refreshes hourly during market hours. Next update: 9:48 PM
Data refreshes hourly during market hours. Next update: 9:48 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MRNA Research Pages
